INT96838

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2001
Last Reported 2010
Negated 4
Speculated 1
Reported most in Body
Documents 25
Total Number 26
Disease Relevance 15.83
Pain Relevance 1.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
lymph node 2
BT-474 2
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
intrathecal 2 96.04 Very High Very High Very High
metalloproteinase 13 90.36 High High
Inflammation 143 89.44 High High
qutenza 7 89.24 High High
COX2 2 84.36 Quite High
methotrexate 2 83.76 Quite High
cva 10 70.08 Quite High
anesthesia 4 69.60 Quite High
abdominal pain 1 64.08 Quite High
Pain 11 63.44 Quite High
Disease Link Frequency Relevance Heat
Apoptosis 140 99.90 Very High Very High Very High
Cancer 1087 99.58 Very High Very High Very High
Triple Negative Breast Cancer 3 99.58 Very High Very High Very High
Carcinoma 18 99.54 Very High Very High Very High
Breast Cancer 839 99.44 Very High Very High Very High
Inflammatory Breast Neoplasms 138 99.24 Very High Very High Very High
Ductal Carcinoma 5 98.74 Very High Very High Very High
Stomach Cancer 16 98.04 Very High Very High Very High
Solid Tumor 25 97.68 Very High Very High Very High
Adenocarcinoma 9 95.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Treatment with 4D5 did not result in outgrowth of cells lacking expression of the HER2/neu receptor.
Negative_regulation (lacking) of Neg (lacking) Gene_expression (expression) of HER2/neu
1) Confidence 0.57 Published 2001 Journal Clin. Cancer Res. Section Abstract Doc Link 11448923 Disease Relevance 0.29 Pain Relevance 0.11
After stratification of patients by histopathology (25 subjects, excluding the only patient with diagnosis on undifferentiated carcinoma), some difference was apparent only for EGFR and HER-2 transcripts.
Negative_regulation (apparent) of Gene_expression (transcripts) of HER-2 associated with carcinoma
2) Confidence 0.42 Published 2010 Journal Journal of Nucleic Acids Section Body Doc Link PMC2911612 Disease Relevance 0.85 Pain Relevance 0.04
Expression of ErbB family members HER2 and HER3 was also downregulated by sulindac metabolites.
Negative_regulation (downregulated) of Gene_expression (Expression) of HER2
3) Confidence 0.42 Published 2010 Journal Cancer Prev Res (Phila) Section Abstract Doc Link 20332299 Disease Relevance 0.05 Pain Relevance 0.05
Treatment with 4D5 did not result in outgrowth of cells lacking expression of the HER2/neu receptor.
Negative_regulation (lacking) of Neg (lacking) Gene_expression (expression) of HER2/neu
4) Confidence 0.41 Published 2001 Journal Clin. Cancer Res. Section Abstract Doc Link 11448923 Disease Relevance 0.29 Pain Relevance 0.11
A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesterone receptor, and positive for HER2/neu protein expression.
Negative_regulation (positive) of Gene_expression (expression) of HER2 associated with ductal carcinoma and breast cancer
5) Confidence 0.41 Published 2009 Journal Gan To Kagaku Ryoho Section Abstract Doc Link 20037338 Disease Relevance 0.83 Pain Relevance 0.07
A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesterone receptor, and positive for HER2/neu protein expression.
Negative_regulation (positive) of Gene_expression (expression) of neu associated with ductal carcinoma and breast cancer
6) Confidence 0.41 Published 2009 Journal Gan To Kagaku Ryoho Section Abstract Doc Link 20037338 Disease Relevance 0.83 Pain Relevance 0.07
Another study showed evidence of a decrease in HER2 expression after neoadjuvant treatment with letrozole [98].
Negative_regulation (decrease) of Gene_expression (expression) of HER2
7) Confidence 0.40 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001217 Disease Relevance 0.42 Pain Relevance 0
Since fluorescent in situ hybridization (FISH) testing has replaced IHC as the gold standard for HER2 assessment, the P024 tumor bank was reassessed using HER1 and HER2 FISH probes, and these data on HER2 gene amplification status were supplemented with 106 tumor samples [40].
Negative_regulation (using) of Gene_expression (probes) of HER2 associated with cancer
8) Confidence 0.40 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.34 Pain Relevance 0
A phase I biomarker substudy, in which patients (n = 33) with various tumor types and various lapatinib doses provided a pre-treatment and a sequential Day 21 biopsy, allowed a pilot exploration of the impact of lapatinib on growth and survival pathways.49 Four patients with a PR had ErbB2 overexpression and high pre-treatment expression of phosphorylated (p) ErbB2, which was inhibited by lapatinib.
Negative_regulation (inhibited) of Gene_expression (expression) of ErbB2 associated with cancer
9) Confidence 0.40 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.75 Pain Relevance 0
However, a substantial number of breast tumors assigned to the ERBB2 subtype lacks ERBB2 protein expression and/or ERBB2 gene amplification [14,15] and ERBB2-positive cancers that express estrogen receptor (ER) fall into the luminal subtypes [11,13,16].
Negative_regulation (lacks) of Gene_expression (expression) of ERBB2 associated with cancer and breast cancer
10) Confidence 0.40 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.20 Pain Relevance 0
First, we used the HerceptTest and the TAB250 antibodies to evaluate the ERBB2 expression but also to compare their detection in relation with the ERBB2-amplification.
Negative_regulation (evaluate) of Gene_expression (expression) of ERBB2
11) Confidence 0.39 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.27 Pain Relevance 0.11
We extended our IHC analysis to define a potential impact of IGF1R and EGFR protein expression in ERBB2-amplified patients.
Negative_regulation (impact) of Gene_expression (expression) of ERBB2
12) Confidence 0.39 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.35 Pain Relevance 0
Pertuzumab inhibits the formation of the HER2 heterodimer, independent of HER2 expression levels, and its binding site does not overlap with the epitope on HER2 that is recognized by trastuzumab (Herceptin) (14,15).
Negative_regulation (inhibits) of Gene_expression (expression) of HER2
13) Confidence 0.38 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.96 Pain Relevance 0.15
Thus, the combined predictive value of HER2 overexpression and nuclear grade was evident regardless of lymph node status.71 Allred and colleagues71 evaluated HER2 expression using immunohistochemistry in 613 patients with node-negative breast cancer enrolled in the Intergroup Study 0011.
Negative_regulation (evaluated) of Gene_expression (expression) of HER2 in lymph node associated with breast cancer
14) Confidence 0.37 Published 2010 Journal Clinical Medicine Insights. Oncology Section Body Doc Link PMC2883240 Disease Relevance 0.70 Pain Relevance 0
In a recent immunophenotypic study of 80 IBC patients compared with 552 non-IBC controls, tissue arrays were used to determine the protein expression of ER, progesterone receptor, EGFR and ERBB2, MIB1, P53, MUC1 and E-cadherin [12].
Spec (determine) Negative_regulation (determine) of Spec (determine) Gene_expression (expression) of ERBB2 associated with inflammatory breast neoplasms
15) Confidence 0.37 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.57 Pain Relevance 0.04
They noted that HER2 expression was detectable in 22% of patients and the concordance rate between IHC and FISH was high at all levels of HER2 positivity [10].
Negative_regulation (detectable) of Gene_expression (expression) of HER2
16) Confidence 0.36 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC2856525 Disease Relevance 0.83 Pain Relevance 0
Assessment of Her2 status
Negative_regulation (Assessment) of Gene_expression (status) of Her2
17) Confidence 0.34 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.29 Pain Relevance 0
Table 1 lists differences in RNA expression values of PAI-1, COX-2 and ERBB2 for paired samples of each patient.
Negative_regulation (values) of Gene_expression (expression) of ERBB2
18) Confidence 0.33 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.24 Pain Relevance 0.13
There will also be great benefit in generating better mouse models of specific types of human breast cancer, ranging from triple negative breast cancer (oestrogen receptor negative, progesterone receptor negative and HER2 negative) to oestrogen receptor positive tumours.
Negative_regulation (negative) of Neg (negative) Gene_expression (negative) of HER2 associated with cancer, triple negative breast cancer and breast cancer
19) Confidence 0.32 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 1.00 Pain Relevance 0
There will also be great benefit in generating better mouse models of specific types of human breast cancer, ranging from triple negative breast cancer (oestrogen receptor negative, progesterone receptor negative and HER2 negative) to oestrogen receptor positive tumours.
Negative_regulation (negative) of Neg (negative) Gene_expression (negative) of HER2 associated with cancer, triple negative breast cancer and breast cancer
20) Confidence 0.32 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 1.00 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox